These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33354933)

  • 1. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
    Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
    Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to aflibercept versus continuing bevacizumab for treatment-resistant neovascular age-related macular degeneration: a one-year comparative observational study.
    Husum YS; Moe MC; Bragadóttir R; Jørstad ØK
    Acta Ophthalmol; 2021 Dec; 99(8):e1354-e1359. PubMed ID: 33638291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
    Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
    Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
    Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.
    Schwartz R; Warwick A; Olvera-Barrios A; Pikoula M; Lee AY; Denaxas S; Taylor P; Egan C; Chakravarthy U; Lip PL; Tufail A;
    Ophthalmol Retina; 2021 Aug; 5(8):e11-e22. PubMed ID: 33866023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project.
    Barthelmes D; Nguyen V; Walton R; Gillies MC; Daien V;
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1839-1846. PubMed ID: 30051312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
    Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S;
    Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
    Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
    Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Grant S; Pirouz A
    Ophthalmol Retina; 2018 Mar; 2(3):225-230. PubMed ID: 31047590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.